Peregrine Capital Management LLC Acquires 15,423 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Peregrine Capital Management LLC lifted its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 436,197 shares of the biotechnology company’s stock after acquiring an additional 15,423 shares during the period. Peregrine Capital Management LLC’s holdings in ADMA Biologics were worth $7,481,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. State Street Corp boosted its stake in ADMA Biologics by 61.4% in the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares during the period. Geode Capital Management LLC lifted its holdings in shares of ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after buying an additional 137,989 shares in the last quarter. Perpetual Ltd bought a new position in shares of ADMA Biologics during the fourth quarter worth $62,300,000. Assenagon Asset Management S.A. grew its stake in ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after acquiring an additional 92,281 shares in the last quarter. Finally, Lord Abbett & CO. LLC bought a new stake in ADMA Biologics in the 3rd quarter valued at $61,858,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $16.17 on Wednesday. The company’s 50-day moving average price is $17.21 and its 200-day moving average price is $17.87. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a market cap of $3.82 billion, a PE ratio of 57.75 and a beta of 0.75. ADMA Biologics, Inc. has a twelve month low of $5.02 and a twelve month high of $23.64.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright increased their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

Insiders Place Their Bets

In other news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.